Triveni Bio CEO Vishal Patel and CSO Jennifer Dovey
Triveni Bio launches with $92M Series A to fund eczema antibody treatment
Triveni Bio has raised $92 million in a Series A financing round as it aims to move its atopic dermatitis antibody into the clinic. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
